סרוקסט

לגאי שלום! באופ כללי, כל התרופות הנלקחות למטרה שנלקח הסרוקסט גורמות לעליה במשקל משפחת התרופות בהן כלול הסרוקסט פועלות במנגנון הגורם לעליה במשקל קטנה יותר מאחרות. אולם בטיפול לאורך זמן הוא גורם לעליה במשקל. סקירת הספרות האחרונה המשווה בין התרופות מצ"ב ואם אתה קורא אנגלית או מישהוא יכול לעזור לך , תוכל להעזר בה J Clin Psychiatry 2000;61 Suppl 11:37-41 Weight gain and antidepressants. Fava M. Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA. Weight gain during antidepressant treatment can be either a sign of improvement in patients who have weight loss as a symptom of depression or a residual symptom in patients who overeat when depressed. However, significant weight gain during the acute phase of treatment or weight gain that continues despite achieving full remission of depressive symptoms is likely to be a side effect of antidepressant treatment. Weight gain is a relatively common problem during both acute and long-term treatment with antidepressants, and it is an important contributing factor to noncompliance. This article will review the literature with regard to the relative risk for weight gain of antidepressants. It appears that tricyclic antidepressants (TCAs) and perhaps monoamine oxidase inhibitors (MAOIs) may be more likely to cause weight gain than the selective serotonin reuptake inhibitors (SSRIs) or the newer antidepressants, with the exception of mirtazapine, which may be placed between the SSRIs and the TCAs in terms of relative risk for weight gain. Paroxetine may be more likely to cause weight gain than the other SSRIs during long-term treatment, and bupropion and nefazodone may be less likely to cause weight gain than the SSRIs in the long term, although more studies are necessary to confirm these impressions.